<DOC>
	<DOCNO>NCT00002594</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . bone marrow transplantation peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow bone marrow transplantation and/or peripheral stem cell transplantation treat patient recurrent medulloblastoma CNS germ cell tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Bone Marrow and/or Peripheral Stem Cell Transplantation Treating Patients With Recurrent Medulloblastoma CNS Germ Cell Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine response progression-free survival patient recurrent medulloblastoma CNS germ cell tumor treat intensive melphalan cyclophosphamide follow autologous bone marrow and/or peripheral blood stem cell rescue . - Determine acute delay toxic effect regimen patient . OUTLINE : Autologous bone marrow and/or peripheral blood stem cell ( PBSC ) harvest . Patients receive intensive cyclophosphamide IV 1 hour day -8 -5 melphalan IV 15 minute day -4 -2 . Bone marrow reinfused day 0 . PBSC reinfused day 0 use alone day 1 use autologous bone marrow transplantation ( ABMT ) . Sargramostim ( GM-CSF ) administer IV 2 hour daily begin 4 hour ABMT continue blood count recover . Patients follow every 6 month year 4 annually thereafter . PROJECTED ACCRUAL : A total 30 patient accrue study within 2.5 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis recurrent medulloblastoma CNS germ cell tumor Histologic review primary intracranial spinal cord tumor require Biopsy reduction tumor bulk prior study encourage require No 1 prior primary therapy ( radiotherapy chemoradiotherapy ) and/or 1 prior salvage therapy Patients progression salvage therapy ineligible Minimal residual disease ( tumor bulk 1.5 cm ) second clinical complete remission ( CR ) Bone marrow infiltration without mass lesion isolate abnormal CSF cytology manifestation recurrent disease allow clinical CR first achieve conventional therapy PATIENT CHARACTERISTICS : Age : 2 25 Performance status : Karnofsky 80100 % Life expectancy : More 8 week Hematopoietic : Absolute neutrophil count great 1,000/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 1.5 mg/dL SGPT le 80 IU Renal : Creatinine le 1.2 mg/dL Cardiovascular : LVEF normal Other : No infection Able tolerate vigorous hydration Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Prior cyclophosphamide ifosfamide allow Endocrine therapy : No concurrent dexamethasone antiemetic Other concurrent corticosteroid allow Radiotherapy : See Disease Characteristics Pretransplantation radiotherapy boost allow Surgery : See Disease Characteristics Pretransplantation surgery allow Other : At least 4 week since prior therapy except corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>recurrent childhood brain tumor</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
</DOC>